Originally developed for the management of obesity and type 2 diabetes, GLP-1 agonists have recently been tested in populations with both obesity and OSA, showing encouraging results in reducing OSA severity through weight loss and possibly other mechanisms. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.